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Abstract 
Background: This study was undertaken to determine the susceptibility profile and the mechanism of antibiotic 
resistance in Group B streptococcus (GBS) isolates detected in vaginal and rectal swabs from pregnant women 
attending Dr George Mukhari Academic Hospital, a University Teaching Hospital in Pretoria, South Africa.
Methods: The samples were collected over an 11-month period, cultured on selective media (colistin and nalidixic 
acid agar and Todd-Hewitt broth), and GBS positively identified by using different morphological and biochemical 
tests. The susceptibility testing was done using the Kirby–Bauer and E test methods according to CLSI guidelines 
2012. The D test method was used for the detection of inducible clindamycin resistance. Multiplex PCR with specific 
primers was used to detect different genes coding for resistance.
Results: Out of 413 samples collected, 128 (30.9 %) were positive with GBS. The susceptibility testing revealed that 
100 % of isolates were sensitive to penicillin, ampicillin, vancomycin and high level gentamicin. Erythromycin and clin-
damycin resistance was 21.1 and 17.2 %, respectively, in which 69 % had harboured constitutive macrolide, lincosa-
mide and streptogramin B (MLSB), 17.4 % had inducible MLSB. The M and L phenotypes were present in 6.8 % each. 
The methylation of target encoded by ermB genes was the commonest mechanism of resistance observed in 55 % of 
isolates, 38 % of isolates had both ermB and linB genes and efflux pump mediated by mefA genes was also distributed 
among the isolates.
Conclusions: The study reaffirmed the appropriateness of penicillin as the antibiotic of choice for treating GBS infec-
tion. However it identified the challenges of resistance to macrolides and lincosamides used as alternative drugs for 
individuals allergic to penicillin. More GBS treatment options for penicillin allergic patients need to be researched on.
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Background
Streptococcus agalactiae (Group B streptococcus, GBS) is 
the leading cause of neonatal infections in humans. It is 
an important cause of illness in pregnant women and the 
elderly with underlying illnesses such as diabetes melli-
tus or immunosuppression [1–3]. The organism is part of 
the normal flora of the gut and genital tract and is found 
colonizing 10–40 % of pregnant women [4].
In adults and pregnant women, GBS can cause urosep-
sis, chorioamnionitis, endometritis, pneumonia, skin and 
soft tissue infections [3, 4]. In newborns GBS is the cause 
of neonatal sepsis, pneumonia, and meningitis [5–7]. 
Mother to child transmission occurs via the ascending 
route from the maternal genital tract into the amniotic 
fluid or at delivery [8]. Infant GBS infection is classi-
fied as early-onset disease (EOD) when occurring from 
birth to 6 days (70–80 % of cases), and late-onset disease 
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(LOD), when it occurs more than 7–90 days after birth; 
this is transmitted from mother or health care personnel 
to infants [9–11].
Penicillin and ampicillin are the antibiotics of choice, 
followed by the first-generation cephalosporins and van-
comycin for the treatment of GBS infections [12, 13]. No 
resistance to penicillin has been reported except a few 
cases of isolates with intermediate sensitivity or reduced 
Minimum Inhibitory Concentrations (MICs) to penicillin 
[14–16]. Alternative antibiotics besides macrolides and 
lincosamide exist for penicillin allergic patients, although 
the use of vancomycin should be reserved for penicillin-
allergic women with a high risk of anaphylaxis [17–19].
Erythromycin resistance mechanism in GBS is mostly 
due to ribosomal modification encoded by erm genes 
(ermB, erm A/TR) or through efflux pump mediated by 
mefA genes that cause resistance to 14- and 15-mem-
bered macrolides, which confers cross-resistance to all 
constitutive macrolide, lincosamide and streptogramin 
B (MLSB) antibiotics [20–22]. This resistance can either 
be inducible (iMLSB) or constitutive (cMLSB) [23, 24]. 
Moreover clindamycin resistance in GBS is less fre-
quent and is due to ribosomal translocation encoded by 
linB genes [25]. Multiplex PCR can be used to detect the 
major erythromycin and clindamycin resistance genes in 
GBS strains [22, 26].
In South Africa there is a lack of sufficient data on 
antibiotic resistance in GBS isolates. The purpose of this 
study was to assess the susceptibility profile of GBS to 
different antibiotics, to determine genetic basis and the 
mechanisms of antibiotic resistance in GBS isolates from 




The procedure for collection was explained to each 
patient before specimens were taken. High vaginal swabs 
(HVS), low vaginal swabs (LVS) and rectal swabs (RS) 
were collected aseptically from pregnant women (age 
18–45  years old); these were at the gestational period 
of 16–38 weeks, attending antenatal clinic at Dr George 
Mukhari Academic Hospital, in Garankuwa. This is a 
University Teaching Hospital associated with the Uni-
versity of Limpopo, Medical University of Southern 
Africa (Medunsa campus), located about 37  km north 
of Pretoria, Gauteng Province, in South Africa. It lies 
at an altitude of about 1350 m (4500 ft) above sea level; 
in a longitude of 25°37′14″S and latitude of 28°1′1. The 
women who indicated that they received antibiotic treat-
ment 2 weeks prior to sample collection were excluded. 
However any women who needed antibiotic treatment 
after collection were referred for clinical management 
accordingly. Samples were collected from February 2012 
until December 2012. Swabs were placed into Amies 
transport medium (Rochelle Chemicals and Lab Equip-
ment, Pretoria, South Africa), properly labelled and put 
into a cooler box containing ice packs, and transported 
to the laboratory at the Department of Microbiologi-
cal Pathology, University of Limpopo, Medunsa campus 
within 2–4  h of collection. Specimens, one per patient 
were cultured onto selective media, 5  % sheep blood, 
Columbia colistin and nalidixic acid (CNA) agar (DMP—
National Health Laboratory Service, Pretoria, South 
Africa) and also inoculated into enriched selective GBS 
broth, Todd-Hewitt broth (DMP—NHLS, Pretoria, South 
Africa), with the same antibiotics concentration as in 
CNA (15 mg/l nalidixic acid and 8 mg/l gentamycin) and 
were incubated for 24–48 h in a 5 % CO2 atmosphere at 
37  °C. Isolates were confirmed as GBS by using the fol-
lowing methods: morphology of bacteria, haemolytic 
activity, catalase test, microscopy (Gram’s stain), bile 
esculin, and CAMP reaction followed by latex agglutina-
tion test (Streptex—Slidex ® Strepto Plus—bioMérieux, 
Marcy l’Etoile, France) for antigen detection.
Antibiotic susceptibility testing
Purification of isolates was done before susceptibility 
testing. Susceptibility testing was done on one isolate per 
patient. For the three methods below, antibiotics were 
placed onto a Muller-Hinton agar added with 5 % sheep 
blood following bacterial inoculation (0.5 McFarland of 
bacterial suspension). The plates were incubated at 37 °C 
in a CO2 enriched environment for 20–24  h. For qual-
ity control, Streptococcus pneumoniae ATCC 49619 and 
Streptococcus agalactiae ATCC 12403 were used as con-
trol strains [16, 27].
Disc diffusion
All the 128 GBS positive isolates were tested by Kirby–
Bauer method for susceptibility to ampicillin (10  μg), 
vancomycin (30 μg), high level gentamycin (120 μg), cip-
rofloxacin (5 μg), chloramphenicol (30 μg), and tetracy-
cline (TE) (30 μg). The results were interpreted according 
the CLSI 2012 guidelines [27].
E test
The MICs of penicillin, erythromycin and clindamycin 
were determined by commercial paper strips or E test 
method (AB Biodisk, Davies-Diagnostics, Pretoria, South 
Africa), following the manufacturer’s instructions.
Double disc diffusion
The detection of inducible clindamycin resistance was 
done by using D test method as previously described [23, 
24, 28]. Briefly, erythromycin (15  µg) and clindamycin 
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(2 µg) disks (Oxoid, Davies-Diagnostics, Pretoria, South 
Africa) were placed 12  mm apart edge to edge [27]. 
Blunting was defined as growth within the clindamycin 
zone of inhibition proximal to the erythromycin disk, 
indicating MLSB-inducible methylation. Resistance to 
both erythromycin and clindamycin indicated MLSB-
constitutive methylation. Resistance to erythromycin but 
susceptibility to clindamycin without blunting indicated 
an efflux mechanism (M phenotype). And finally resist-
ance to clindamycin but susceptible to erythromycin was 




DNA extraction was done using the Zymo Research—
DNA MiniPrep-Kit (Zymo-Research—USA, Inqaba 
Biotechnical Industries, Pretoria, South Africa) and fol-
lowing the manufacturer instructions.
Multiplex PCR
All phenotypically resistant GBS isolates were tested to 
detect three genes for erythromycin resistance, ermB, 
ermTR, mefA and one gene for clindamycin resistance 
linB using a set of specific primers (Table  1) as previ-
ously described [22, 28–30]. The primers were synthe-
sized at Inqaba—Biotechnical industries, Pretoria, South 
Africa. Briefly, a 50 µl PCR contained 2.5 mM Tris–HCl 
pH 8.6, 2.5 mM KCl, 2.5 mM MgCl2, 5 mM dNTP, 0.5 U 
Taq DNA polymerase (Thermo Scientific—Phusion Flash 
High-Fidelity PCR Master Mix, AB, Inqaba—Biotech-
nical Industry, Pretoria, South Africa), PCR water, and 
1 µM primers pairs forwards and reverses. A total of 5 µl 
template DNA was used in the PCR. The cycling condi-
tions on a My Cycler™ thermal cycler (BioRad Labora-
tories, London, UK) consisted of a single cycle of 95  °C 
for 3 min followed by 35 cycles of denaturation at 95 °C 
for 1 min, annealing at 57 °C for 1 min and extension at 
72 °C for 1 min. A final extension step of 72 °C for 5 min 
was followed by a hold at 4 °C as previously described by 
Desjardins et al. [28].
Agarose gel
The different genes of resistance were analyzed based 
on presence or absence of bands in the agarose gel. 
Electrophoresis on 1 % agarose gels in 40 mM Tris ace-
tate–2  mM EDTA buffer was used to distinguish PCR 
products as previously described [4], and bands were 
visualized using Gel Docs (BioRad Laboratories, London, 
UK). A culture of GBS ATCC 49447 strain was used as 
negative control.
Ethical considerations
The women recruited in the study gave informed and 
signed consent. The study was approved by the Medi-
cal Research and Ethics Committee of South Africa 
(MREC/P/02/2011: IR) and Directorate for Health and 
Social Affairs (Medical University of Southern Africa; 
MEDUNSA) and the College of Agriculture and Envi-
ronmental Health Sciences, University of South Africa 
(UNISA).
Results
Of the 413 pregnant women recruited, 128 (30.9 %) were 
colonized with GBS in which 70 were recovered from 
Todd-Hewitt broth and 58 from CNA agar (22/58 RS, 
9/58 LVS, 3/58 HVS and 24/58 all the sites). The sus-
ceptibility pattern was performed on 128 positive GBS 
isolates against 9 antimicrobial agents and results are 
presented in Tables 2 and 3 showing susceptibility profile 
of GBS isolates by disc diffusion method and by E test, 
respectively. All strains were 100  % susceptible to peni-
cillin, ampicillin, vancomycin and high level gentamycin. 
However resistant strains to erythromycin and clindamy-
cin were observed in 21.1 and 17.2  %, respectively. The 
strains that were resistant to tetracycline were 94.5 % of 
the isolates, 24.9  % were resistant to chloramphenicol 
and 18.6 % resistant to ciprofloxacin (all the intermediate 
Table 1 PCR primers used for detection of resistance genes in GBS
Gene Primers Primers sequence (5′–3′) Products size (bp) References
ermB ermB1 5′_-GAA AAG GTA CTC AAC CAA ATA-3′_(F) 640 [22, 29]
ermB2 5′_-AGT AAC GGT ACT TAA ATT GTT TAC-3′_(R)
ermTR ermTR1 5′_-GAA GTT TAG CTT TCC TAA-3′_(F) 400 [22, 28]
ermTR2 5′_-GCT TCA GCA CCT GTC TTA ATT GAT-3′_(R)
mefA mefA1 5′_-AGT ATC ATT AAT CAC TAG TGC-3′_(F) 348 [22, 29]
mefA2 5′_-TTC TTC TGG TAC TAA AAG TGG-3′_(R)
linB linB1 5′_-CCT ACC TAT TGT TTG TGG AA-3′_(F) 944 [22]
linB2 5′_-ATA ACG TTA CTC TCC TAT TC-3′_(R)
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values were considered as resistant). The MIC range for 
penicillin was found to be between 0.012 and 0.12 μg/ml 
and that for erythromycin and clindamycin both ranged 
between 0.02 and 0.25 μg/ml. All erythromycin and clin-
damycin resistant isolates were screened for resistance 
genes.
The phenotype (by double-disc diffusion) and genotype 
results of resistant isolates are summarized in Table  4. 
Among the resistant isolates to both erythromycin and 
clindamycin, 69 % harboured constitutive MLSB, 17.4 % 
harboured inducible MLSB, the M phenotypes were pre-
sent in 6.8 % and L phenotypes in 6.8 %.
The genotypic analysis of all isolates irrespective of 
whether they were resistant or sensitive phenotypically, 
was done using Multiplex PCR. This showed that the 
methylation of target encoded by ermB genes was the 
commonest mechanism of resistance observed in 55  % 
(16/29) of isolates, and efflux pump mediated by mefA 
genes were found in 3.4 % of isolates, ermTR genes were 
also found in 3.4 % of isolates and finally both ermB and 
linB were observed in 38 % (11/29) of isolates. The PCR 
products of isolates with resistant genes were distin-
guished by agarose gel electrophoresis as shown in Fig. 1.
Discussion
In our study the colonization rate was 30.9 %, the high-
est reported so far in South Africa. The susceptibility 
testing was performed on 128 GBS isolated against 9 
Table 2 Susceptibility profile of GBS isolates (n = 128)
* The intermediate values were assimilated to resistant
Antibiotic/method Susceptible Intermediate* Resistant
Disc diffusion
 Ampicillin 128 (100 %) – –
 Vancomycin 128 (100 %) – –
 Gentamicin-high level 128 (100 %) – –
 Ciprofloxacin 104 (81.2 %) 17 (13.3 %) 7 (5.5 %)
 Chloramphenicol 96 (75.0 %) 11 (8.6 %) 21 (16.4 %)
 Tetracycline 7 (5.5 %) 10 (7.8 %) 111 (86.7 %)
Table 3 Susceptibility profile of GBS isolates by E test (n = 128)
a CLSI guidelines 2012
Antibiotic MIC (µg/ml)
Range 50 % of isolates 90 % of isolates Break pointa (susceptible) % Of isolates resistant
Penicillin 0.002–32 0.012 0.047 ≤0.12 –
Erythromycin 0.016–256 0.16 8 ≤0.25 21.1
Clindamycin 0.016–256 0.16 8 ≤0.25 17.2
Table 4 Minimum inhibitory concentrations of  eryth-
romycin and  clindamycin resistant isolates, D-shape 
and screened genes (n = 29)
S susceptible, R resistant, I intermediate, cMLSB MLSB-constitutive methylation 
[erythro (R), clinda (R)], iMLSB MLSB-inducible methylation [erythro (R), clinda 
(S) with blunting], M-phenotype efflux pump mechanism [erythro (R), clinda (S) 
without blunting], L-phenotype erythro (S), clinda (R)





1 1 (R) 0.50 (I) Negative cMLSB ermB
2 3 (R) 0.75 (I) Negative cMLSB linB + ermB
3 0.75 (I) 0.75 (I) Negative cMLSB linB + ermB
4 0.50 (I) 0.047 (S) Negative M pheno-
type
mefA
5 0.75 (I) 1 (R) Negative cMLSB ermB
6 4 (R) 0.50 (I) Negative cMLSB ermB
7 1 (R) 0.38 (I) Negative cMLSB ermB
8 0.75 (I) 1 (R) Negative cMLSB ermB
9 0.75 (I) 4 (R) Negative cMLSB linB + ermB
10 4 (R) 7 (R) Negative cMLSB ermB
11 2 (R) 0.047 (S) Positive iMLSB ermTR
12 1.5 (R) 0.016 (S) Positive iMLSB ermB
13 0.75 (I) 0.50 (I) Negative cMLSB linB + ermB
14 8 (R) 0.38 (I) Negative cMLSB ermB
15 0.25 (S) 2 (R) Negative L phenotype linB + ermB
16 8 (R) 1 (R) Negative cMLSB linB + ermB
17 0.75 (I) 1 (R) Negative cMLSB ermB
18 3 (R) 0.38 (I) Negative cMLSB ermB
19 1 (R) 0.38 (I) Negative cMLSB ermB
20 1.5 (R) 0.25 (S) Positive iMLSB ermB
21 0.25 (S) 1 (R) Negative L phenotype linB + ermB
22 3 (R) 0.047 (S) Positive iMLSB ermB
23 0.50 (I) 0.75 (I) Negative cMLSB linB + ermB
24 2 (R) 8 (R) Negative cMLSB ermB
25 0.75 (I) 0.50 (I) Negative cMLSB linB + ermB
26 0.75 (I) 0.094 (S) Negative M pheno-
type
ermB
27 4 (R) 0.023 (S) Positive iMLSB ermB
28 0.50 (I) 1 (R) Negative cMLSB linB + ermB
29 0.75 (I) 0.50 (I) Negative cMLSB linB + ermB
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antimicrobial agents. All strains were 100  % susceptible 
to penicillin, ampicillin, vancomycin and high level gen-
tamycin. This is similar to a study conducted in Germany 
and to an Ethiopian study in which 100 % of isolates were 
found to be sensitive to penicillin, ampicillin, high-level 
gentamycin and vancomycin [12, 31]. Similar findings 
were also described in studies from the USA and Argen-
tina where 100 % sensitivity to penicillin, ampicillin and 
vancomycin [4, 23].
Our findings slightly differ with those described in a 
study from the neighbouring country of Zimbabwean in 
which almost 100 % of isolates were sensitive to penicillin, 
but 2 % were intermediate susceptible to penicillin [8].
In this study 94.5  % of the isolates were resistant to 
tetracycline, 24.9 % resistant to chloramphenicol, 21.1 % 
resistant to erythromycin, 18.6  % resistant to ciproflox-
acin and 17.2  % resistant to clindamycin. Considering 
erythromycin and clindamycin resistance rates, similar 
findings were reported in Canada, in which erythromy-
cin and clindamycin resistant rates were found in 17 and 
8 %, respectively [28]. This is again similar to a Tanzanian 
study that reported a GBS resistance rate of 17.6 and 13 % 
for erythromycin and clindamycin, respectively and to 
that described in the Malawian study where the erythro-
mycin resistance rate was 21 % [32, 33]. This suggests that 
antibiotic resistance in GBS may be similar despite differ-
ent geographic locations in sub-Saharan Africa. However 
phylogenetic studies are necessary to verify this. Erythro-
mycin and clindamycin resistance rates in these studies 
were far lower when compared to the 50.7 % of erythro-
mycin resistance and 38.4 % clindamycin resistance rates 
reported by Back et  al. [18] in the USA, and far lower 
again than the 54 and 33  %, respectively reported by 
DiPersio et al. [34]. Erythromycin and clindamycin resist-
ance rates in our findings were higher when compared to 
the Canadian study, where there was 8  % resistance for 
erythromycin and 4.5 % for clindamycin [30].
The 94.5  % tetracycline resistance rate found in our 
study is similar to the 96 % reported by Gray et al. [33], to 
the 86.8 % reported by De Azavedo et al. [30], and 100 % 
reported by Moyo et  al. [8]. Resistance to tetracycline 
might be explained by wide and indiscriminate use of 
these antibiotics worldwide.
In our study, the phenotypic testing by double disk dif-
fusion revealed that 29 isolates were resistant to either 
erythromycin alone or clindamycin alone or to both 
erythromycin and clindamycin in which 20 (69  %) iso-
lates harboured cMLSB, 5 (17.2 %) harboured iMLSB, the 
M phenotypes were present in 2 (6.8 %) isolates and the 
L phenotypes in 2 (6.8 %). This finding was in agreement 
with a Canadian study in which 47.2 % had cMLSB resist-
ance phenotype, 40  % had an iMLSB resistance pheno-
type, and 12.7 % of the isolates displayed M phenotypes 
[26]. In Ireland, a study found similar findings with 40 % 
of isolates that harboured iMLSB, 36 % had cMLSB, 24 % 
M phenotype and no L phenotype [24].
Considering the genotypic analysis by multiplex PCR, 
erythromycin and clindamycin resistance in GBS were 
mainly associated with ermB genes with 55 % of isolates, 
ermTR genes harboured 3.4  % and mefA genes 3.4  % of 
the isolates, both ermB and linB genes together were pre-
sent in 38 % of the isolates, and none of the strains car-
ried both ermB and ermTR nor both mefA and erm nor 
linB alone. This was similar to a French study in which 
ermB was found in 47 % of isolates, ermTR genes in 45 % 
of isolates and mefA gene in 6 % of the isolates and none 
of the strains carried both ermB and ermTR or both mefA 
and erm genes [17].
In this study, there were two isolates which were phe-
notypically sensitive to erythromycin, and their erm 
Fig. 1 Result of Multiplex PCR of GBS isolates resistant to erythromycin and clindamycin. Lane 8 DNA Molecular Weight Marker Hyper Ladder™ 
50 bp (BioLine). Lane 14 negative control (GBS ATCC 49447). Lane 1, 6, 7, 10, 11, 13, 15 presence of ermB genes, 640 bp, (sample no 15, 63, 65, 125, 
148, 182, 183). Lane 2, 4, 9, 12, 16 presence of both ermB genes and linB genes, 944 bp (sample no 32, 57, 191,159, 184). Lane 5 presence of ermTR 
gene, 400 bp (sample no 83). Lane 3 presence of mefA gene, 348 bp (sample no 60)
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genes were also detected by molecular testing. This 
may be due to erm gene not being expressed, but will 
require further studies to confirm the interpretation. 
Also two isolates were resistant to clindamycin but no 
resistance mechanism was found. This situation could 
be explained by the fact that isolates may harbour 
mutations in genes coding for 23S rRNA. A similar 
situation was also reported in an Irish study where no 
recognized resistance mechanisms were found in nine 
isolates [24].
The limitations of the study were that the positive con-
trol strain (resistant to both erythromycin and clindamy-
cin) was not available during the molecular stage of the 
study; thus only negative controls were used. Data from 
previous local studies in South Africa were not available 
to allow comparison of genetic mechanisms underlying 
resistance in GBS.
Conclusion
This study confirmed the appropriateness of penicil-
lin as still being the antibiotic of choice for treating 
GBS infections in South Africa. The concern which 
still remains is the reported increase in the resistance 
to the macrolides and clindamycin used as alternative 
drugs for penicillin allergic patients, in other parts of 
the world. More GBS treatment options for penicillin 
allergic patients need to be explored. The methylation 
of targets encoded by ermB was the commonest mecha-
nisms of resistance observed and efflux pump mediated 
by mefA genes was also distributed among the isolates. 
More research studies need to be done in various areas 
and populations of South Africa to determine GBS 
colonization.
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